Plasma Metabolic Biomarkers for Gastric Cancer Diagnosis

NCT06109805 | Completed

• 1 other identifier: BFHHZML20230010
• Study Type: observational
• Target: 1,706
• Locations: 1 country
• Sites: 4

Brief Summary

The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from gastric cancer patients using advanced mass spectrometry detection technology, in conjunction with both broad-spectrum and targeted metabolomics approaches. The goal is to construct a dedicated plasma metabolite database for gastric cancer patients. Simultaneously, we will delve into the exploration and validation of a series of metabolic biomarkers for early gastric cancer diagnosis. The objective is to establish a safer, more convenient, and more sensitive early screening method, thereby providing a reliable scientific foundation and critical evidence for improving the early diagnostic process for individuals at high risk of gastric cancer.

Conditions

Gastric Cancer

Outcome Measures

Primary Outcomes (1)

• Plasma metabolite content

  The outcome will be tested by metabolomics detection technology based on mass spectrometry

  Before receiving treatment for gastric cancer

Study Arms (2)

Gastric cancer group

Patients diagnosed with gastric cancer, including early gastric cancer and advanced gastric cancer

Other: Gastric cancer

Non-gastric cancer group

Patients diagnosed with benign gastric diseases or healthy controls

Interventions

Gastric cancer OTHER

Patients diagnosed with gastric cancer, including early gastric cancer and advanced gastric cancer

Gastric cancer group

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population included a range of subjects with gastric and non-gastric cancer, including patients with benign gastric disease and healthy controls, who were admitted to the main study center and other collaborating sub-center hospitals.

You may qualify if:

• Confirmed diagnosis of gastric cancer or benign gastric diseases through gastroscopy and pathological examination.
• Collection of plasma samples prior to surgical treatment.
• Availability of complete clinical data.

You may not qualify if:

• Previous reception of anti-tumor treatments (including radiotherapy, chemotherapy, etc.) before blood collection.
• Coexistence of other systemic tumors.
• Absence of plasma sample collection before surgical treatment.
• Incomplete clinical data.
• Pregnancy status.

Sponsors & Collaborators

• Beijing Friendship Hospital: lead

Study Sites (4)

Beijing Friendship Hospital, Capital Medical University

Beijing, China

Location

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, China

Location

Renmin Hospital of Wuhan University

Wuhan, China

Location

Tongji Hospital, Tongji Medical College of HUST

Wuhan, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Only metabolites will be detected and analyzed in this study.

MeSH Terms

Conditions

Stomach Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases

Study Officials

• Li Min, Ph.D.

  Beijing Friendship Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Deputy Director of Science and Technology Department

Study Record Dates

• First Submitted: October 26, 2023
• First Posted: October 31, 2023
• Study Start: October 20, 2023
• Primary Completion: February 18, 2025
• Study Completion: February 18, 2025
• Last Updated: February 20, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share

Locations

CN (4)